Lyra therapeutics announces first patient treated in phase 2 beacon clinical trial of lyr-220 in post-surgical chronic rhinosinusitis patients

Watertown, mass. , april 25, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose, and throat (ent) passages and other diseased tissues, today announced that the first patient was treated in the part 1/non-randomized portion of the phase 2 beacon clinical trial of lyr-220 in adult patients with chronic rhinosinusitis (crs) who have had a prior sinus surgery.
LYRA Ratings Summary
LYRA Quant Ranking